Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS)

被引：0
|
作者：
Guo, Xi [1 ]
Zhou, Yuhong [1 ]
Zhuang, Rongyuan [1 ]
Zhang, Chenlu [1 ]
You, Yang [1 ]
Li, Wei [1 ]
Wang, Zhiming [1 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11572
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)
    Guo, X.
    Zhou, Y.
    Zhuang, R.
    Zhang, C.
    You, Y.
    Li, W.
    Wang, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S1044 - S1044
  • [2] Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS).
    Naito, Yoichi
    Kawai, Akira
    Araki, Nobuhito
    Ozaki, Toshifumi
    Sugiura, Hideshi
    Yazawa, Yasuo
    Morioka, Hideo
    Matsumine, Akihiko
    Hiraiwa, Masahide
    Asami, Shun
    Isu, Kazuo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Anlotinib rechallenge combined with immune checkpoint inhibitor for advanced soft tissue sarcoma after the failure of anlotinib.
    Fu, Yang
    Jiang, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma
    Seetharam, Mahesh
    Kolla, Kantha R.
    Chawla, Sant P.
    FUTURE ONCOLOGY, 2018, 14 (16) : 1531 - 1545
  • [5] Treatment results in elderly patients (pts) diagnosed with locally advanced soft tissue sarcoma (STS)
    Paterczyk, H. M. Kosela
    Teterycz, P.
    Kozak, K.
    Klimczak, A.
    Switaj, T.
    Rogala, P.
    Jagodzinska-Mucha, P.
    Sobczuk, M. Polaczek P.
    Mariuk-Jarema, A.
    Kopec, S.
    Placzke, J.
    Dudzisz-Sledz, M. E.
    Ostaszewski, K.
    Rutkowski, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1115 - S1115
  • [6] Efficacy and safety of eribulin in the treatment of advanced adult soft tissue sarcoma (STS): First real-world data in Chinese population.
    Guo, Xi
    Zhou, Yuhong
    Zhuang, Rongyuan
    You, Yang
    Zhang, Chenlu
    Wang, Zhiming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] A phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).
    Loong, Herbert H. F.
    Blackstein, Martin E.
    Gupta, Abha A.
    Hogg, David
    Mackay, Helen
    Dhani, Neesha C.
    Oza, Amit M.
    Moore, Malcolm J.
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).
    Loong, Herbert H. F.
    Blackstein, Martin E.
    Gupta, Abha A.
    Hogg, David
    Culala, Lindsay
    Nyquist-Schultz, Kjirsten
    Baker, Stephanie
    Wang, Lisa
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] The efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcoma
    Ni, Ying
    Dong, Yabing
    Jiang, Aijun
    Zhang, Qun
    Wang, Zhantong
    Liang, Hui
    Zhang, Wei
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [10] Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study
    Liu, Jie
    Deng, Yaotiao
    Wang, Ying
    Zhang, Jie
    Li, Mei
    Jiang, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345